Kiniksa Pharmaceuticals Ltd

$10.72 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.

Stock Analysis

last close $10.96
1-mo return -7.3%
3-mo return -22.5%
avg daily vol. 253.68T
52-week high 24.7
52-week low 10.62
market cap. $374M
forward pe -
annual div. -
roe -77.6%
ltg forecast -80.8%
dividend yield -
annual rev. $8M
inst own. 91.8%

Subscribe now for daily local and international financial news